ea0098c25 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023
Fidelman MD Nicholas
, Keenan MD, PhD Bridget P.
, Oh MD David Y.
, Fong MD Lawrence
, Chan BS Kira
, Zhang PhD Li
, Bergsland MD Emily K.
, Hope MD Thomas A.
Background: Expected progression free survival (PFS) for patients with grade 3 well-differentiated neuroendocrine tumors (WD NET) treated with peptide receptor radionuclide therapy (PRRT) is approximately 9 months, and objective response rate (ORR) is 35%. Response rate to single agent immune checkpoint inhibitors (ICI) for patients with G1-3 NET is <15%. Delivery of targeted radiation using PRRT may potentiate the anti-tumor immune response. The purpose of this study is t...